Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

The correlates and consequences of multimorbidity in Singapore

Tristan Manalac
23 Nov 2019
More stay-home care and support from the community will be provided to elderly residents of other districts.

Individuals who are older, female, of lower socioeconomic status and who suffer from mental disorders are more likely to experience increasing multimorbidity, according to a recent Singapore study.

“These findings emphasize the association between multimorbidity and sociodemographic factors,” said researchers. “Healthcare policies need to take sociodemographic factors into account when tackling multimorbidity in a population.”

Accessing the deidentified Singapore Eastern Regional Health System database, researchers identified 1,181,024 individuals (mean age, 39.6±22.1 years; 51.2 percent female) for inclusion in the present population-based cross-sectional study. More than a quarter (26.2 percent) had multimorbidity, which was defined as the presence of two or more chronic conditions. [JAMA Netw Open 2019;2:e1915245]

Multimorbidity occurred at a higher frequency in females than in males (26.8 percent vs 25.6 percent). Only 2.9 percent of the study population had both physical and mental diseases.

Age also emerged as a potential predictor of multimorbidity. The mean number of chronic diseases increased with age, such that more than half of the participants had at least one chronic condition by 50 years. A similar proportion was positive for multimorbidity by 60 years of age.

An inverse effect was observed for socioeconomic status. Multimorbidity was reported in 41.6 percent of participants in the low socioeconomic bracket, more than twice that in the high bracket (20.1 percent). The prevalence of multimorbidity in participants 40–60 years of age in the lowest socioeconomic bracket was similar to their high-status counterparts who were 10 years older.

Mental health was likewise an important consideration for multimorbidity. The two shared a direct proportionality which was mediated by socioeconomic status. That is, mental health issues were significantly more prevalent among those in the lower brackets (5.2 percent vs 2.1 percent; p<0.001), in accordance with excess multimorbidity burden.

Females were also more likely than males to have mental health conditions, reflecting the sex-based asymmetry in multimorbidity burden.

“Such an understanding of the epidemiologic characteristics and the implications of multimorbidity is necessary for better risk stratification of multimorbidity, integrated coordination of multiple appointments for patients and more effective communication among healthcare professionals to better manage patients’ varied clinical needs,” said the researchers.

Aside from sociodemographic determinants, the researchers also determined the impact of multimorbidity on healthcare use. Those with diabetes and renal disease, for example, had the highest polyclinic comorbid care costs. Angina with renal disease comorbidities was associated with the highest emergency department costs.

Patients suffering from osteoarthritis-related chronic conditions and asthma incurred the greatest general practitioner visit costs. The highest specialist outpatient costs were recorded in patients with comorbid cancer and chronic kidney disease.

Overall, “[t]hese findings suggest that holistic management of multimorbidity is warranted, and care must be customized to meet the needs of patients with different multimorbidity patterns,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.